TENX
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Supports a bullish reading. Current ratio 14.56 · operating margin 0.0%
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Interesting trend — weekly bias down
ACHAT TOTAL: 63 850 titres (~121 847,19 $ US)
- Insiders
- Doogan DeclanGiordano Christopher Thomas
- Total bought
-
$121,847
Avg buy (VWAP, 90d window) $1.91 vs last close $1.94 (+1.5%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-09-16
- Liquidity
- Thin $11,026,695/day · 20d vol
- Last synced
-
2026-09-22 21:11:01
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-16 | Doogan Declan | Buy | 53,000 | $1.92 | $101,760 | Form 4 |
| 2026-09-15 | Giordano Christopher Thomas | Buy | 4,850 | $1.82 | $8,837 | Form 4 |
| 2026-09-11 | Giordano Christopher Thomas | Buy | 6,000 | $1.88 | $11,250 | Form 4 |
| 2026-09-11 | STAAB THOMAS R II | Buy | 5,675 | $1.94 | $10,981 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-09-22
TENX presents a deeply unfavorable risk/reward profile: despite adequate liquidity, the company is pre-revenue with persistently negative operational cash flows and no viable near-term path to profitability.
The first sentence of the analysis written for TENX on 2026-09-22 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 14.565 | 20.602 | 3.258 | 1.736 | 3.638 | |
| Quick Ratio | 14.565 | 20.602 | 3.258 | 1.736 | 3.638 | |
| Solvency Ratio | -7.350 | -3.751 | -2.148 | -5.719 | -18.520 | |
| Cash Ratio | 13.634 | 20.211 | 2.730 | 1.149 | 3.570 | |
| Price To Earnings Ratio | -9.097 | -5.383 | -0.708 | -0.296 | -0.659 | |
| Price To Earnings Growth Ratio | -0.551 | 0.056 | 0.007 | 0.004 | -0.035 | |
| Forward Price To Earnings Growth Ratio | -0.551 | 0.056 | 0.007 | 0.004 | -0.035 | |
| Price To Earnings Diluted Ratio | -9.097 | -5.383 | -0.708 | -0.296 | -0.659 | |
| Price To Earnings Diluted Growth Ratio | -0.551 | 0.056 | 0.007 | 0.004 | -0.035 | |
| Price To Book Ratio | 4.925 | 1.028 | 0.674 | 2.188 | 5.041 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -13.354 | -6.383 | -0.925 | -0.272 | -1.970 | |
| Price To Operating Cash Flow Ratio | -13.354 | -6.383 | -0.925 | -0.272 | -1.971 | |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.043 | 0.237 | 0.049 | |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.062 | 0.541 | 0.069 | |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.058 | 0.351 | 0.064 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.074 | 1.051 | 1.443 | 2.281 | 1.412 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -5.003 | -3.156 | -1.646 | -6.501 | -6.941 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | 0.000 | -764.304 | -14.630 | -17.384 | -34,103.717 | |
| Interest Coverage Ratio | 0.000 | -847.565 | -343.556 | -2,487.653 | -34,487.082 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -11.787 | -19.242 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -11.787 | -14.869 | -37.335 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 | -5,162.386 | -2,067.061 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 | -5,162.386 | -2,067.061 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -7.234 | 0.018 | 0.499 | -0.178 | -0.498 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 14.565 | ▼-6.037 | ▲5.805 |
| Quick Ratio | 14.565 | ▼-6.037 | ▲5.805 |
| Solvency Ratio | -7.350 | ▼-3.600 | ▲0.147 |
| Cash Ratio | 13.634 | ▼-6.577 | ▲5.375 |
| Price To Earnings Ratio | -9.097 | ▼-3.714 | ▼-5.869 |
| Price To Earnings Growth Ratio | -0.551 | ▼-0.607 | ▼-0.447 |
| Forward Price To Earnings Growth Ratio | -0.551 | ▼-0.607 | ▼-0.447 |
| Price To Earnings Diluted Ratio | -9.097 | ▼-3.714 | ▼-5.869 |
| Price To Earnings Diluted Growth Ratio | -0.551 | ▼-0.607 | ▼-0.447 |
| Price To Book Ratio | 4.925 | ▲3.897 | ▲2.154 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -13.354 | ▼-6.971 | ▼-8.773 |
| Price To Operating Cash Flow Ratio | -13.354 | ▼-6.971 | ▼-8.773 |
| Debt To Assets Ratio | 0.000 | 0.000 | ▼-0.066 |
| Debt To Equity Ratio | 0.000 | 0.000 | ▼-0.134 |
| Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.095 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.074 | ▲0.023 | ▼-0.378 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -5.003 | ▼-1.847 | ▼-0.353 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | ▼-0.000 |
| Debt Service Coverage Ratio | 0.000 | ▲764.304 | ▲6980.007 |
| Interest Coverage Ratio | 0.000 | ▲847.565 | ▲7633.171 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲6.206 |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲12.798 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | ▲1445.889 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | ▲1445.889 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -7.234 | ▼-7.252 | ▼-5.755 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $478.1M | $94.5M | $5.5M | $3.3M | $21.4M | |
| Enterprise value | $380.5M | -$319K | -$3.8M | $2.0M | $16.1M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -10.63x | 0.02x | 0.65x | -0.16x | -1.48x | |
| EV / Free cash flow | -10.63x | 0.02x | 0.65x | -0.16x | -1.48x | |
| EV / EBITDA | -7.23x | 0.02x | 0.50x | -0.18x | -0.50x | |
| Net debt / EBITDA | 1.85x | 5.40x | 1.21x | 0.12x | 0.16x | |
| Current ratio | 14.56x | 20.60x | 3.26x | 1.74x | 3.64x | |
| Income quality | 0.68x | 0.84x | 0.77x | 1.09x | 0.33x | |
| Graham net-net | $2 | $6 | $25 | $12 | $298 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.1% | 100.3% | 100.0% | 100.0% | |
| Working capital | $97.1M | $92.0M | $8.1M | $1.4M | $4.1M | |
| Invested capital | $97.1M | $92.0M | $8.1M | $1.5M | $4.4M | |
| Return on assets | -50.5% | -18.2% | -66.0% | -324.5% | -541.9% | |
| Operating ROA | -56.1% | -36.0% | -109.1% | -235.2% | -509.0% | |
| Return on tangible assets | -50.5% | -18.2% | -66.0% | -324.5% | -541.9% | |
| Return on equity | -54.2% | -19.1% | -95.2% | -740.1% | -765.1% | |
| Return on invested capital | -58.1% | -21.2% | -95.8% | -480.4% | -721.6% | |
| Return on capital employed | -58.1% | -21.2% | -101.7% | -709.9% | -739.1% | |
| Earnings yield | -11.0% | -18.6% | -141.3% | -338.2% | -151.8% | |
| Free cash flow yield | -7.5% | -15.7% | -108.2% | -367.9% | -50.8% | |
| Capex / Op. cash flow | 0.0% | 0.0% | 0.0% | -0.0% | -0.0% | |
| Capex / Depreciation | 0.0% | 0.0% | 0.0% | 2.1% | 4.8% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+405.7%EV / Sales n/aEV / EBITDA ▼-39945.0%EV / Op. cash flow ▼-10.650Earnings yield ▲+0.076
Profitability
Return on equity ▼-0.351Return on assets ▼-0.323Return on invested capital ▼-0.369Return on capital employed ▼-0.369Operating ROA ▼-0.202Income quality ▼-0.161Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-6.037Net debt / EBITDA ▼-3.541Working capital ▲+5078000.000Invested capital ▲+5078000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+2134.0%EV / Sales n/aEV / EBITDA ▼-1353.6%EV / Op. cash flow ▼-9.145Earnings yield ▲+1.408
Profitability
Return on equity ▲+7.109Return on assets ▲+4.915Return on invested capital ▲+6.635Return on capital employed ▲+6.810Operating ROA ▲+4.528Income quality ▲+0.346Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+10.927Net debt / EBITDA ▲+1.691Working capital ▲+92945978.000Invested capital ▲+92651178.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-09-20 Insider Buying: Tenax Therapeutics (NASDAQ:TENX) Director Buys $101,760.00 in Stock Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) Director Declan Doogan purchased 53,000 shares of the firm''s stock in a transaction that occurred on Wednesday, September 16th. The stock was purchased at an average price of $1.92 per share, with a total value of $101,760.00. Following the purchase, the director directly owned 55,274 shares of
- 2026-09-01 Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that Chris Giordano, President & Chief Executive Officer, will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET.
- 2026-08-29 Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112)
- 2026-08-19 Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky Tenax Therapeutics (TENX) Securities Investigation Notice - Levi and Korsinsky PR Newswire NEW YORK, Aug. 19, 2026
- 2026-08-19 Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky Tenax Therapeutics shares fell approximately 84% to 85% after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations on behalf of TENX investors who suffered losses.
- 2026-08-17 Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Tenax Therapeutics (TENX) Tenax Therapeutics shares lost roughly 84% to 85% of their value after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations. Tenax Therapeutics shares lost roughly 84% to 85% of their value after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations.
- 2026-08-16 TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law [url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
- 2026-08-16 TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $TENX--TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law.
- 2026-08-14 TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX) A single clinical readout drove Tenax Therapeutics (NASDAQ: TENX) shares down approximately 84% to 85% shareholder after the Company disclosed that its Phase 3
- 2026-08-14 TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX) NEW YORK--(BUSINESS WIRE)--A single clinical readout drove Tenax Therapeutics (NASDAQ: TENX) shares down approximately 84% to 85% shareholder after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. If you held TENX shares and suffered a loss, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The.